158 related articles for article (PubMed ID: 25479328)
21. Oxidation pattern of the anticancer drug ellipticine by hepatic microsomes - similarity between human and rat systems.
Stiborová M; Borek-Dohalská L; Aimová D; Kotrbová V; Kukacková K; Janouchová K; Rupertová M; Ryslavá H; Hudecek J; Frei E
Gen Physiol Biophys; 2006 Sep; 25(3):245-61. PubMed ID: 17197724
[TBL] [Abstract][Full Text] [Related]
22. Molecular mechanisms of antineoplastic action of an anticancer drug ellipticine.
Stiborova M; Rupertova M; Schmeiser HH; Frei E
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2006 Jul; 150(1):13-23. PubMed ID: 16936898
[TBL] [Abstract][Full Text] [Related]
23. Role of cytochromes P450 and peroxidases in metabolism of the anticancer drug ellipticine: additional evidence of their contribution to ellipticine activation in rat liver, lung and kidney.
Stiborova M; Moserova M; Mrazova B; Kotrbova V; Frei E
Neuro Endocrinol Lett; 2010; 31 Suppl 2():26-35. PubMed ID: 21187821
[TBL] [Abstract][Full Text] [Related]
24. Polymer-drug compatibility: a guide to the development of delivery systems for the anticancer agent, ellipticine.
Liu J; Xiao Y; Allen C
J Pharm Sci; 2004 Jan; 93(1):132-43. PubMed ID: 14648643
[TBL] [Abstract][Full Text] [Related]
25. Oxidation of an antitumor drug ellipticine by peroxidases.
Poljaková J; Forsterová K; Sulc M; Frei E; Stiborová M
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2005 Dec; 149(2):449-53. PubMed ID: 16601808
[TBL] [Abstract][Full Text] [Related]
26. Role of hepatic cytochromes P450 in bioactivation of the anticancer drug ellipticine: studies with the hepatic NADPH:cytochrome P450 reductase null mouse.
Stiborová M; Arlt VM; Henderson CJ; Wolf CR; Kotrbová V; Moserová M; Hudecek J; Phillips DH; Frei E
Toxicol Appl Pharmacol; 2008 Feb; 226(3):318-27. PubMed ID: 17976674
[TBL] [Abstract][Full Text] [Related]
27. Vacuolar-ATPase-mediated intracellular sequestration of ellipticine contributes to drug resistance in neuroblastoma cells.
Hrabeta J; Groh T; Khalil MA; Poljakova J; Adam V; Kizek R; Uhlik J; Doktorova H; Cerna T; Frei E; Stiborova M; Eckschlager T
Int J Oncol; 2015 Sep; 47(3):971-80. PubMed ID: 26134421
[TBL] [Abstract][Full Text] [Related]
28. Covalent binding of the anticancer drug ellipticine to DNA in V79 cells transfected with human cytochrome P450 enzymes.
Frei E; Bieler CA; Arlt VM; Wiessler M; Stiborová M
Biochem Pharmacol; 2002 Jul; 64(2):289-95. PubMed ID: 12123750
[TBL] [Abstract][Full Text] [Related]
29. Cytochrome P450- and peroxidase-mediated oxidation of anticancer alkaloid ellipticine dictates its anti-tumor efficiency.
Stiborová M; Rupertová M; Frei E
Biochim Biophys Acta; 2011 Jan; 1814(1):175-85. PubMed ID: 20576524
[TBL] [Abstract][Full Text] [Related]
30. DNA adduct formation by the anticancer drug ellipticine in human leukemia HL-60 and CCRF-CEM cells.
Poljaková J; Frei E; Gomez JE; Aimová D; Eckschlager T; Hrabeta J; Stiborová M
Cancer Lett; 2007 Jul; 252(2):270-9. PubMed ID: 17306925
[TBL] [Abstract][Full Text] [Related]
31. The anticancer drug ellipticine activated with cytochrome P450 mediates DNA damage determining its pharmacological efficiencies: studies with rats, Hepatic Cytochrome P450 Reductase Null (HRN™) mice and pure enzymes.
Stiborová M; Černá V; Moserová M; Mrízová I; Arlt VM; Frei E
Int J Mol Sci; 2014 Dec; 16(1):284-306. PubMed ID: 25547492
[TBL] [Abstract][Full Text] [Related]
32. Preparation of pH-responsive polymer core-shell nanospheres for delivery of hydrophobic antineoplastic drug ellipticine.
Wang H; Yang L; Rempel GL
Macromol Biosci; 2014 Feb; 14(2):166-72. PubMed ID: 24106137
[TBL] [Abstract][Full Text] [Related]
33. Use of micellar media for the fluorimetric determination of ellipticine in aqueous solutions.
Sbai M; Lyazidi SA; Lerner DA; del Castillo B; Martin MA
J Pharm Biomed Anal; 1996 Jun; 14(8-10):959-65. PubMed ID: 8818001
[TBL] [Abstract][Full Text] [Related]
34. Cytochrome b5 increases cytochrome P450 3A4-mediated activation of anticancer drug ellipticine to 13-hydroxyellipticine whose covalent binding to DNA is elevated by sulfotransferases and N,O-acetyltransferases.
Stiborová M; Indra R; Moserová M; Cerná V; Rupertová M; Martínek V; Eckschlager T; Kizek R; Frei E
Chem Res Toxicol; 2012 May; 25(5):1075-85. PubMed ID: 22390216
[TBL] [Abstract][Full Text] [Related]
35. Self-assembling peptide-based nanoparticles enhance anticancer effect of ellipticine in vitro and in vivo.
Wu Y; Sadatmousavi P; Wang R; Lu S; Yuan YF; Chen P
Int J Nanomedicine; 2012; 7():3221-33. PubMed ID: 22802684
[TBL] [Abstract][Full Text] [Related]
36. Isolation and partial characterization of the adduct formed by 13-hydroxyellipticine with deoxyguanosine in DNA.
Moserova M; Kotrbova V; Rupertova M; Naiman K; Hudecek J; Hodek P; Frei E; Stiborova M
Neuro Endocrinol Lett; 2008 Oct; 29(5):728-32. PubMed ID: 18987592
[TBL] [Abstract][Full Text] [Related]
37. Excited state proton transfer dynamics of an eminent anticancer drug, ellipticine, in octyl glucoside micelle.
Gavvala K; Koninti RK; Sengupta A; Hazra P
Phys Chem Chem Phys; 2014 Jul; 16(28):14953-60. PubMed ID: 24931633
[TBL] [Abstract][Full Text] [Related]
38. [In vitro stimulation by ellipticine derivatives of DNA cleavage induced by DNA topoisomerase II: a structure-activity relationship].
Fossé P; Charra M; Paoletti C; Saucier JM; René B
Bull Cancer; 1994 Mar; 81(3):194-202. PubMed ID: 7894127
[TBL] [Abstract][Full Text] [Related]
39. The anticancer agent ellipticine unwinds DNA by intercalative binding in an orientation parallel to base pairs.
Canals A; Purciolas M; Aymamí J; Coll M
Acta Crystallogr D Biol Crystallogr; 2005 Jul; 61(Pt 7):1009-12. PubMed ID: 15983425
[TBL] [Abstract][Full Text] [Related]
40. Drug-loaded and superparamagnetic iron oxide nanoparticle surface-embedded amphiphilic block copolymer micelles for integrated chemotherapeutic drug delivery and MR imaging.
Hu J; Qian Y; Wang X; Liu T; Liu S
Langmuir; 2012 Jan; 28(4):2073-82. PubMed ID: 22047551
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]